Raymond James Financial Inc. Makes New Investment in Fractyl Health, Inc. (NASDAQ:GUTS)

Raymond James Financial Inc. bought a new stake in shares of Fractyl Health, Inc. (NASDAQ:GUTS) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 16,400 shares of the company’s stock, valued at approximately $34,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. BNP Paribas Financial Markets boosted its holdings in Fractyl Health by 54.1% in the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after purchasing an additional 7,397 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Fractyl Health by 27.3% during the 4th quarter. Bank of New York Mellon Corp now owns 41,448 shares of the company’s stock valued at $85,000 after buying an additional 8,886 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Fractyl Health during the 3rd quarter valued at approximately $25,000. Rhumbline Advisers grew its position in shares of Fractyl Health by 73.1% during the fourth quarter. Rhumbline Advisers now owns 25,626 shares of the company’s stock worth $53,000 after buying an additional 10,826 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Fractyl Health by 335.4% in the third quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock worth $37,000 after buying an additional 11,406 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, Morgan Stanley reduced their price objective on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd.

Insider Buying and Selling

In other Fractyl Health news, CEO Harith Rajagopalan sold 90,972 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.82, for a total transaction of $165,569.04. Following the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $894,218.78. This represents a 15.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jay David Caplan sold 22,346 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.81, for a total transaction of $40,446.26. Following the completion of the transaction, the insider now owns 153,544 shares in the company, valued at approximately $277,914.64. The trade was a 12.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Fractyl Health Stock Performance

Shares of GUTS stock opened at $1.01 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The stock has a market capitalization of $49.41 million, a price-to-earnings ratio of -0.08 and a beta of 0.30. Fractyl Health, Inc. has a one year low of $0.87 and a one year high of $7.89. The company’s 50-day simple moving average is $1.34 and its 200-day simple moving average is $1.91.

Fractyl Health (NASDAQ:GUTS) last released its earnings results on Monday, March 3rd. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). Equities analysts anticipate that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.